The FTC issued 156 warning letters to supplement and wellness brands last year. An efficacy claim on your label — even one you believe is accurate — can trigger an inquiry. Here's what regulatory defense coverage pays for and why standard General Liability won't respond.
The Federal Trade Commission's primary jurisdiction over supplement and wellness brands centers on advertising claims — and they define advertising broadly. Your product label is advertising. Your website is advertising. Your Amazon listing is advertising. Your Instagram posts are advertising. Any claim you make about what your product does, prevents, supports, or improves is subject to FTC scrutiny, and the standard for substantiation is more rigorous than most founders realize when they're writing their first label.
Efficacy claims are the most common trigger. "Clinically proven to support cognitive function." "Scientifically tested for immune health." "Backed by research." These phrases trigger an FTC substantiation standard that requires competent and reliable scientific evidence — typically two randomized controlled human clinical trials, not a handful of rodent studies or supplier-provided research summaries. If you can't produce that evidence when the FTC asks, the inquiry becomes a formal investigation, and the legal costs begin accumulating immediately.
Before-and-after claims and testimonials that imply typical results are a close second. The FTC's endorsement guides require that testimonials reflect the typical experience of consumers who use the product, not cherry-picked success stories. A testimonial that says "I lost 30 pounds using this supplement" must be accompanied by a disclosure about typical results if most users don't achieve similar outcomes. Most supplement brands violate this rule without knowing it, and the FTC has been actively enforcing it in recent enforcement cycles.
Disease claims that cross the FDA/FTC line are particularly dangerous because they can trigger both agencies simultaneously. Claiming that your supplement "reduces inflammation associated with arthritis" crosses from a structure/function claim (FDA territory) into a disease claim (requiring an FDA-approved new drug application). Brands that blur this line face simultaneous FTC advertising inquiry and FDA enforcement action — two separate legal responses running in parallel, each requiring separate legal counsel.
General liability insurance covers two primary things: bodily injury and property damage claims by third parties. If a consumer claims your supplement caused them physical harm and sues your brand, GL may respond to that bodily injury claim. If your product damages a retailer's property during a delivery and they sue, GL may respond. These are third-party liability scenarios involving physical harm or property loss.
What GL explicitly does not cover is regulatory defense. An FTC inquiry is not a lawsuit brought by a consumer who was physically injured. It's a government regulatory action challenging the substantiation of advertising claims. There's no bodily injury. There's no property damage. There's no third-party plaintiff in the traditional tort sense. Standard GL policies have regulatory exclusions that explicitly carve out government enforcement actions, and those exclusions are written broadly enough to encompass the vast majority of FTC advertising inquiries supplement brands face.
Some founders assume their commercial umbrella policy will pick up where GL leaves off. It won't. Umbrella policies follow the same form as the underlying GL — the exclusions carry through. Others assume their E&O (errors and omissions) or professional liability policy will respond. E&O coverage is designed for service businesses and professional services, not product companies. The coverage territory doesn't overlap with FTC regulatory defense in the way founders hope.
The coverage category you actually need is specifically designed for regulatory proceedings — sometimes sold as a rider on a broader management liability package, sometimes as a standalone regulatory defense endorsement. The key language to look for is coverage for "regulatory investigation costs," "government inquiry response," and specifically "FTC and FDA enforcement proceedings." Without language that specifically addresses government regulatory actions, you don't have regulatory defense coverage — regardless of what your broker tells you.
When the FTC contacts your brand — whether through a formal civil investigative demand (CID), a warning letter, or an informal inquiry — the clock starts. You need regulatory counsel immediately, not after you've spent three weeks trying to figure out whether your GL policy will respond. Regulatory defense coverage pays for the legal counsel required to respond to the FTC's demands, draft your substantiation documentation, negotiate with FTC staff attorneys, and represent your brand through the inquiry process.
Relabeling costs are a significant component that many founders overlook. If the FTC determines that your label claims need to be modified as part of a consent order or voluntary corrective action, the cost of destroying existing inventory, redesigning the label, re-printing, and re-manufacturing falls on your brand. For a supplement brand with $200,000 in finished goods inventory, forced relabeling can be a catastrophic cash event. Regulatory defense coverage that includes relabeling cost reimbursement protects you from this outcome.
FTC response documentation is labor-intensive. The FTC will ask for every piece of substantiation behind every claim — research studies, expert declarations, consumer testing data, historical advertising materials, internal communications about claim development. Compiling this documentation while running a business requires either dedicated legal and regulatory staff (which pre-Series A brands don't have) or outside counsel billing at $400–$600 per hour. Coverage that includes documentation costs prevents a manageable inquiry from becoming an existential financial event.
The simplest self-audit framework is to ask, for every claim on your label and website: do I have two randomized controlled human clinical trials substantiating this? If the answer is no, the claim needs to be either removed, qualified with appropriate language, or supported by a substantiation study before you go to market. The FTC's substantiation standard for health-related claims is not aspirational — it's what you'll be asked to produce when the inquiry letter arrives.
Structure/function claims require specific language under FDA regulations. "Supports immune health" is a permissible structure/function claim if substantiated and accompanied by the required FDA disclaimer. "Prevents colds and flu" is a disease claim that requires FDA drug approval. The line is real, it's enforced, and your label copy needs to be reviewed by regulatory counsel who knows where it falls — not by your marketing team or your supplement formulator.
Annual label claim reviews tied to your policy renewal are the most cost-effective risk management step supplement and wellness brands can take. Regulatory counsel review of a full label and website typically runs $3,000–$8,000. That's less than a single day of FTC inquiry response billing. Build it into your compliance calendar, document that you've done it, and keep the review memo on file. If the FTC ever does inquire, that documented review demonstrates good-faith compliance effort — which matters in settlement negotiations.